Healthcare Industry News: lumbar interbody fusion
News Release - April 23, 2007
Jeffrey Wang, M.D. Joins CoreSpine Technologies' Medical Advisory BoardProminent Spine Surgeon Begins Important Advisory Role with Growing Spine Company
MINNEAPOLIS, April 23 (HSMN NewsFeed) -- CoreSpine Technologies(TM), LLC, an emerging spinal device company located in Minneapolis, Minnesota announced the addition of Jeffrey Wang, M.D. as a Medical Advisory Board member.
"Dr. Wang's experience in emerging and existing spinal therapies compliments the company's existing Medical Advisory Board members," said Christine Horton, Co-Founder of CoreSpine. Christine continued, "In addition to his surgical experiences as the Chief of Spine Services and Co-Director of the UCLA Spine Center, Dr. Wang's academic career as an Associate Professor of Orthopedics at UCLA brings a strong, new component to our Medical Advisory Board."
"I believe the need for CoreSpine's device is understood by many spine surgeons familiar with emerging spinal technologies," said Dr. Wang. "And while these technologies are exciting we have existing procedures, such as Transforaminal lumbar interbody fusion (TLIF), which could use this device today." Dr. Wang went on to say, "I look forward to working with CoreSpine and contributing to the company's success through my active role on the Medical Advisory Board."
About CoreSpine Technologies, LLC
CoreSpine Technologies is a privately held company founded in June 2005. The company's mission is to develop enabling technologies for use with evolving spinal technologies, including the areas of motion preservation and fusion. CoreSpine's first product focuses on the complete mechanical removal of nucleus tissue from the lumbar disc space, while sparring all annular and endplates tissues. For additional information, please contact Christine Horton at firstname.lastname@example.org or Britt Norton at email@example.com or visit the company's website at http://www.corespinetech.com.
Source: CoreSpine Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.